2003
Implications of the presence and length of “geographic miss” on restenosis and the edge phenomenon in the INHIBIT trial
Costantini CO, Lansky AJ, Mintz GS, Shirai K, Teirstein PS, Stone G, Vandertie L, Proctor B, Fahy M, Yeung A, Raizner AE, Waksman R, Leon MB. Implications of the presence and length of “geographic miss” on restenosis and the edge phenomenon in the INHIBIT trial. The American Journal Of Cardiology 2003, 91: 1261-1265. PMID: 12745117, DOI: 10.1016/s0002-9149(03)00280-7.Peer-Reviewed Original Research
2002
Use of localised intracoronary β radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial
Waksman R, Raizner AE, Yeung AC, Lansky AJ, Vandertie L, investigators I. Use of localised intracoronary β radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. The Lancet 2002, 359: 551-557. PMID: 11867107, DOI: 10.1016/s0140-6736(02)07741-3.Peer-Reviewed Original ResearchMeSH KeywordsBrachytherapyCoronary RestenosisElectrocardiographyEndpoint DeterminationFemaleHumansMaleMiddle AgedPhosphorus RadioisotopesStentsTreatment OutcomeConceptsBinary angiographic restenosis ratePrimary safety endpointAngiographic restenosis rateTarget lesion revascularisationStent restenosisPlacebo groupSafety endpointRestenosis rateRadiated groupMyocardial infarctionMajor adverse cardiac eventsIntracoronary beta radiationIntracoronary β-radiationSuccessful coronary interventionAdverse cardiac eventsPrimary efficacy endpointRecurrence of restenosisBeta-radiation treatmentEfficacy endpointAngiographic outcomesCardiac eventsCoronary interventionIntracoronary stentingProcedural successVascular brachytherapy